Dna Or Rna Fragments Or Modified Forms Thereof (e.g., Genes, Etc.) Patents (Class 536/23.1)
  • Patent number: 10273501
    Abstract: A method of altering a eukaryotic cell is provided including transfecting the eukaryotic cell with a nucleic acid encoding RNA complementary to genomic DNA of the eukaryotic cell, transfecting the eukaryotic cell with a nucleic acid encoding an enzyme that interacts with the RNA and cleaves the genomic DNA in a site specific manner, wherein the cell expresses the RNA and the enzyme, the RNA binds to complementary genomic DNA and the enzyme cleaves the genomic DNA in a site specific manner.
    Type: Grant
    Filed: July 2, 2015
    Date of Patent: April 30, 2019
    Assignee: President and Fellows of Harvard College
    Inventors: George M. Church, Prashant G. Mali, Luhan Yang
  • Patent number: 10273261
    Abstract: Embodiments of the present disclosure relate generally to reporter compositions which are synthetic nucleotides that comprise nucleotides with a high charge mass moiety attached thereto via a linker molecule. The linker molecules can vary in length in part to enable the high charge mass moiety to extend out from a DNA polymerase complex so that polymerization may not be influenced.
    Type: Grant
    Filed: January 3, 2017
    Date of Patent: April 30, 2019
    Assignee: QUANTUMDX GROUP LIMITED
    Inventors: Jonathan J. O'Halloran, Joseph H. Hedley
  • Patent number: 10266843
    Abstract: The present invention provides, among other things, multimeric coding nucleic acids that exhibit superior stability for in vivo and in vitro use. In some embodiments, a multimeric coding nucleic acid (MCNA) comprises two or more encoding polynucleotides linked via 3? ends such that the multimeric coding nucleic acid compound comprises two or more 5? ends.
    Type: Grant
    Filed: April 7, 2017
    Date of Patent: April 23, 2019
    Assignee: Translate Bio, Inc.
    Inventors: Frank DeRosa, Michael Heartlein, Daniel Crawford, Shrirang Karve
  • Patent number: 10266586
    Abstract: Provided herein are therapeutic agents having specificity for human CLPTM1 L polypeptide, including therapeutic agents comprising one or more CLPTM1 L-targeting agents, compositions comprising such therapeutic agents, and methods of using such compositions for treating or preventing a cancer, pre-cancerous lesion, or other disease condition associated with CLPTM1 L protein dysfunction (e.g., pathogenic production, modification, or function).
    Type: Grant
    Filed: January 6, 2015
    Date of Patent: April 23, 2019
    Assignee: The Medical College of Wisconsin, Inc.
    Inventor: Michael A. James
  • Patent number: 10214723
    Abstract: The present invention relates to a method of producing a non-human, mammalian oocyte carrying a modified target sequence in its genome, the method comprising the steps of introducing into a non-human, mammalian oocyte: (a) a clustered, regularly interspaced, short palindromic repeats (CRISPR)-associated protein 9 (Cas9 protein) or a nucleic acid molecule encoding said Cas9 protein; and (b-i) a target sequence specific CRISPR RNA (crRNA) and a trans-activating crRNA (tracr RNA) or a nucleic acid molecule encoding said RNAs; or (b-ii) a chimaeric RNA sequence comprising a target sequence specific crRNA and tracrRNA or a nucleic acid molecule encoding said RNA; wherein the Cas9 protein introduced in (a) and the RNA sequence(s) introduced in (b-i) or (b-ii) form a protein/RNA complex that specifically binds to the target sequence and introduces a single or double strand break within the target sequence.
    Type: Grant
    Filed: July 13, 2016
    Date of Patent: February 26, 2019
    Assignee: HELMHOLTZ ZENTRUM MÜNCHEN DEUTSCHES FORSCHUNGSZENTRUM FÜR GESUNDHEIT UND UMWELT
    Inventors: Ralf Kühn, Wolfgang Wurst, Oskar Ortiz Sanchez
  • Patent number: 10202411
    Abstract: Provided herein are compounds, compositions and methods for the treatment of Flaviviridae infections, including HCV infections. In certain embodiments, compounds and compositions of nucleoside derivatives are disclosed, which can be administered either alone or in combination with other anti-viral agents. In certain embodiments, the compounds are 3?-substituted methyl or alkynyl nucleosides of Formula I: (I); or a pharmaceutically acceptable salt, solvate, stereoisomeric form, tautomeric form or polymorphic form thereof, wherein Base, PD, RA, RB1, RB2, RC and Z are as defined herein.
    Type: Grant
    Filed: April 16, 2015
    Date of Patent: February 12, 2019
    Assignee: IDENIX PHARMACEUTICALS LLC
    Inventors: David Dukhan, Cyril B. Dousson, Gilles Gosselin, Jean-Laurent Paparin, Guillaume Brandt, Rachid Rahali, Aurelien Salanson, François-René Alexandre
  • Patent number: 10196418
    Abstract: Aspects of the present disclosure include compositions that make use of phosphorus and/or nucleobase protecting groups which find use in the synthesis of long polynucleotides. Phosphorus protecting groups are provided that help increase the stepwise coupling yield and/or phosphorous protecting groups that can be removed during the oxidation step. Amidine nucleobase protecting groups are provided that find use in the subject compositions and methods which provides for e.g., increased resistance to depurination during polynucleotide synthesis. In some instances, the methods and compositions disclosed herein utilize a combination of the phosphorus and amidine nucleobase protecting groups in the synthesis of polynucleotides having a sequence of 200 or more monomeric units in length. Also provided are methods for synthesizing a polynucleotide (e.g., a DNA) using one or more compounds disclosed herein.
    Type: Grant
    Filed: April 30, 2015
    Date of Patent: February 5, 2019
    Assignee: Agilent Technologies, Inc.
    Inventors: Douglas J. Dellinger, Luca Monfregola, Marvin Caruthers, Mithun Roy
  • Patent number: 10195264
    Abstract: The invention uses polypeptide antigens and/or OMVs to immunize against serogroups A, C, W135 and Y (and against serogroup Y in particular). Serogroup B polypeptides can achieve this protection, thus permitting a single polypeptide-based vaccine to be used for protecting against all of serogroups A, B, C, W135 and Y.
    Type: Grant
    Filed: April 22, 2005
    Date of Patent: February 5, 2019
    Assignee: GLAXOSMITHKLINE BIOLOGICALS S.A.
    Inventors: Mario Contorni, Marzia Giuliani, Mariagrazia Pizza
  • Patent number: 10188115
    Abstract: The present invention discloses Hemipteran insect inhibitory proteins, methods of using such proteins, nucleotide sequences encoding such proteins, methods of detecting and isolating such proteins, and their use in agricultural systems.
    Type: Grant
    Filed: July 17, 2017
    Date of Patent: January 29, 2019
    Assignee: Monsanto Technology LLC
    Inventors: James A. Baum, Artem G. Evdokimov, Farhad Moshiri, Timothy J. Rydel, Eric J. Sturman, Moritz von Rechenberg, Halong Vu, Andrew M. Wollacott, Meiying Zheng
  • Patent number: 10182560
    Abstract: Various aspects provided herein relate to compositions and methods for altering the content of polyunsaturated fatty acids in animals, e.g., non-human animals. Transgenic animals (e.g., non-human animals) that are capable of converting carbohydrates and/or saturated fats to polyunsaturated fatty acids (e.g., n-6 and/or n-3 fatty acids) and uses thereof are also provided herein.
    Type: Grant
    Filed: March 20, 2015
    Date of Patent: January 22, 2019
    Assignee: THE GENERAL HOSPITAL CORPORATION
    Inventor: Jing X. Kang
  • Patent number: 10159755
    Abstract: The present invention relates to an improved RNA transcription vector, which is very suitable for the production of mRNA for in vivo therapeutic purposes. The improvements in the vector reside in the presence of a translation enhancer (TE) and a nuclear retention element (NRS), especially when the latter is the “Expression and Nuclear Retention Element” (ENE) of Kaposi's sarcoma associated Herpes virus (KSHV).
    Type: Grant
    Filed: November 12, 2014
    Date of Patent: December 25, 2018
    Assignee: Vrije Universiteit Brussel
    Inventors: Carlo Heirman, Kristiaan Thielemans
  • Patent number: 10150791
    Abstract: The present disclosure relates to photoactivable protecting groups containing a diarylsulfide chromophore, a method for the synthesis thereof and their use as photoactivable protecting groups using maskless photolithography based array synthesis.
    Type: Grant
    Filed: February 6, 2017
    Date of Patent: December 11, 2018
    Assignee: Roche Diagnostics Operations, Inc.
    Inventor: Klaus-Peter Stengele
  • Patent number: 10150966
    Abstract: Provided is a novel useful microRNA having improved anti-tumor activity, obtained by introducing a variation in a microRNA which is present in-vivo and which exhibits an anti-tumor effect. This microRNA containing a base sequence (SEQ ID NO: 1) obtained by varying a predetermined region of the base sequence of miR-29b is able to exhibit a particularly outstanding anti-tumor effect.
    Type: Grant
    Filed: March 4, 2015
    Date of Patent: December 11, 2018
    Inventors: Hirofumi Yamamoto, Masaki Mori
  • Patent number: 10144950
    Abstract: The invention provides methods, compositions, kits and devices for the detection of target molecules. In some embodiments, the invention allows for multiplexed target molecule detection.
    Type: Grant
    Filed: January 31, 2012
    Date of Patent: December 4, 2018
    Assignee: ROCHE SEQUENCING SOLUTIONS, INC.
    Inventor: Garry P. Nolan
  • Patent number: 10138507
    Abstract: Described are methods for production of RNA transcripts using a non-amplified, linearized DNA template in an in vitro transcription reaction. Enzymatic 5? capping and oligo dT purification can also be included in the methods.
    Type: Grant
    Filed: March 13, 2014
    Date of Patent: November 27, 2018
    Assignee: ModernaTX, Inc.
    Inventors: Stephane Bancel, William Joseph Issa, John Grant Aunins, Tirtha Chakraborty
  • Patent number: 10131911
    Abstract: Described are post transcriptionally chemically modified double strand RNAs (MdsRNAs) having more than 30 base pairs. The MdsRNAs inhibit gene expression in target organisms. Also described are methods of making and using MdsRNAs.
    Type: Grant
    Filed: November 6, 2017
    Date of Patent: November 20, 2018
    Assignee: nanoSUR LLC
    Inventors: Juan P. Arhancet, Sreevishnu Cheerla, Graciela B. Arhancet, David B. Rozema
  • Patent number: 10131912
    Abstract: The invention provides compositions and methods for reducing expression of a target gene in a cell, involving contacting a cell with an isolated double stranded nucleic acid (dsNA) in an amount effective to reduce expression of a target gene in a cell. The dsNAs of the invention possess a pattern of deoxyribonucleotides (in most embodiments, the pattern comprises at least one deoxyribonucleotide-deoxyribonucleotide base pair) designed to direct the site of Dicer enzyme cleavage within the dsNA molecule. Deoxyribonucleotides of the dsNA molecules of the invention are located within a region of the dsNA that can be excised via Dicer cleavage to generate an active siRNA agent that no longer contains the deoxyribonucleotide pattern (e.g., deoxyribonucleotide-deoxyribonucleotide base pairs). Such DNA-extended Dicer-substrate siRNAs (DsiRNAs) were demonstrated to be more effective RNA inhibitory agents than corresponding double stranded RNA-extended DsiRNAs.
    Type: Grant
    Filed: July 10, 2014
    Date of Patent: November 20, 2018
    Assignee: DICERNA PHARMACEUTICALS, INC.
    Inventor: Bob Dale Brown
  • Patent number: 10125162
    Abstract: Described herein are oligosaccharide-oligonucleotide conjugates useful as vaccines against one or more human or veterinary therapeutic indications, and methods of synthesizing and identifying them. The conjugates may be identified using non-human antibodies as binding targets, thereby expanding the power and scope of the invention. Efficacious conjugates may be identified through an iterative screening process.
    Type: Grant
    Filed: June 19, 2015
    Date of Patent: November 13, 2018
    Assignee: Brandeis University
    Inventors: Isaac J. Krauss, Lizbeth K. Hedstrom, Iain S. MacPherson
  • Patent number: 10119138
    Abstract: The invention relates to iRNA agents, which preferably include a monomer in which the ribose moiety has been replaced by a moiety other than ribose that further includes a tether having one or more linking groups, in which at least one of the linking groups is a cleavable linking group. The tether in turn can be connected to a selected moiety, e.g., a ligand, e.g., a targeting or delivery moiety, or a moiety which alters a physical property. The cleavable linking group is one which is sufficiently stable outside the cell such that it allows targeting of a therapeutically beneficial amount of an iRNA agent (e.g., a single stranded or double stranded iRNA agent), coupled by way of the cleavable linking group to a targeting agent—to targets cells, but which upon entry into a target cell is cleaved to release the iRNA agent from the targeting agent.
    Type: Grant
    Filed: September 9, 2016
    Date of Patent: November 6, 2018
    Assignee: Alnylam Pharmaceuticals, Inc.
    Inventors: Muthiah Manoharan, Kallanthottathil G. Rajeev
  • Patent number: 10111874
    Abstract: Combination therapies for treatment of cancers associated with mutations in the KRAS gene are provided. Compositions comprising therapeutic agents for treatment of cancers associated with mutations in the KRAS gene are also provided.
    Type: Grant
    Filed: September 18, 2015
    Date of Patent: October 30, 2018
    Assignee: Araxes Pharma LLC
    Inventors: Matthew Robert Janes, Matthew Peter Patricelli, Liansheng Li, Pingda Ren, Yi Liu
  • Patent number: 10098940
    Abstract: The disclosure relates to immunogenic and vaccine compositions comprising Streptococcus exotoxins and/or bacterial thermolysins from M4 protease family. Also provided are kits, methods and uses of said compositions for treating or preventing laminitis in a hooved animal.
    Type: Grant
    Filed: June 19, 2015
    Date of Patent: October 16, 2018
    Assignee: University of Saskatchewan
    Inventor: David G. Wilson
  • Patent number: 10093700
    Abstract: The present invention relates to ?-PNA monomers according to Formula I where substituent groups R1, R2, R3, R4, R5, R6, B and P are defined as set forth in the specification. The invention also provides methodology for synthesizing compounds according to Formula I and methodology for synthesizing PNA oligomers that incorporate one or more Formula I monomers.
    Type: Grant
    Filed: October 23, 2015
    Date of Patent: October 9, 2018
    Assignee: CARNEGIE MELLON UNIVERSITY
    Inventors: Danith H. Ly, Srinivas Rapireddy, Bichismita Sahu
  • Patent number: 10059943
    Abstract: The present invention relates to new triphosphate-modified oligonucleotides which may act as RIG-I ligands as well as a new method allowing the synthesis and purification in high yield and purity suitable for pharmaceutical applications.
    Type: Grant
    Filed: September 26, 2013
    Date of Patent: August 28, 2018
    Assignee: Rheinische Friedrich-Wilhelms-Universität Bonn
    Inventors: Marion Goldeck, Jasper Van Den Boorn, János Ludwig, Christine Schuberth-Wagner
  • Patent number: 10046006
    Abstract: Methods for reducing recruitment, migration, or both recruitment and migration of polymorphonuclear cells to a site of inflammation in an organ of a human patient comprise administering locally to the organ or systemically to the patient in need thereof an isolated oligonucleotide selected from the group consisting of SEQ ID NO: 8 (IDX9059); SEQ ID NO: 14 (IDX9052); SEQ ID NO: 7 (IDX9054); SEQ ID NO: 6 (IDX9045); SEQ ID NO: 1 (IDX9005); SEQ ID NO: 9 (IDX9074); SEQ ID NO: 3 (IDX9022); SEQ ID NO: 2 (IDX9010); SEQ ID NO: 4 (IDX9030); and SEQ ID NO: 13 (IDX0150).
    Type: Grant
    Filed: October 10, 2014
    Date of Patent: August 14, 2018
    Assignee: InDex Pharmaceuticals AB
    Inventors: Charlotte Admyre, Lars-Göran Axelsson, Oliver Von Stein, Arezou Zargari
  • Patent number: 10048267
    Abstract: In one aspect, a homogenous assay method for determination of blood levels of legumain molecules (an asparaginyl endopeptidase) is disclosed. In one aspect, the assay utilizes specific sizes of nanoparticles that are coated with antibody or antibodies specifically towards legumain molecule or its fragment(s). In one aspect, the assay is designed in a homogenous manner with a dynamic range from 0.2 to 160 ng/mL. In another aspect, disclosed herein is a kit for assaying blood levels of legumain comprising two parts of reagents (R1 and R2), which kit is adaptable to be used on clinical chemistry analyzers. In one aspect, the cut-off values for differentiating normal from high risk of cancers such as breast cancer, colorectal cancer and stomach cancer are 18±3 ng/mL.
    Type: Grant
    Filed: October 30, 2015
    Date of Patent: August 14, 2018
    Assignee: NINGBO ZIYUAN MEDICAL DEVICES INC.
    Inventors: Xiaohong Yu, Fang Guo
  • Patent number: 10048263
    Abstract: The method of the invention allows confirmation of infections caused by Streptococcus agalactiae bacterial species. The method employs a specific reaction of immunoreactive proteins obtained from clinical isolates of Streptococcus agalactiae with antibodies present in the serum of patients.
    Type: Grant
    Filed: March 28, 2014
    Date of Patent: August 14, 2018
    Assignees: Uniwersytet Jagiellonski, Instytut Immunologii I Terapii Doswiadczainej Im. Ludwika Hirszfelds Pan
    Inventors: Monika Brzychczy-Wloch, Sabina Górska, Ewa Brzozowska, Andrzej Gamian, Piotr Heczko
  • Patent number: 10041061
    Abstract: The invention provides methods for extraction of fungal (e.g., yeast spp., filamentous fungal spp.) nucleic acid (e.g., DNA, RNA) from a sample (e.g., be human or veterinary clinical or research samples, agricultural samples, agricultural commodity samples, food products, or environmental samples). In some embodiments, the present invention provides enhanced nucleic acid extraction from samples comprising fungal cell(s) wherein enzymatic (e.g., lysostaphin treatment, lyticase treatment) sample treatment is performed in combination with mechanical (e.g., bead beating) sample treatment.
    Type: Grant
    Filed: September 23, 2011
    Date of Patent: August 7, 2018
    Assignee: IBIS BIOSCIENCES, INC.
    Inventors: Gerard Gundling, Thomas Laffler, Cristina A. Ivy, Lendell Cummins
  • Patent number: 10041073
    Abstract: The present invention relates to RNAi constructs with minimal double-stranded regions, and their use in gene silencing. RNAi constructs associated with the invention include a double stranded region of 8-14 nucleotides and a variety of chemical modifications, and are highly effective in gene silencing. The RNAi constructs may be, for instance, miRNA constructs that are miRNA modulators.
    Type: Grant
    Filed: March 23, 2011
    Date of Patent: August 7, 2018
    Assignee: RXi Pharmaceuticals Corporation
    Inventors: Anastasia Khvorova, William Salomon, Joanne Kamens, Dmitry Samarsky, Tod M. Woolf, James Cardia
  • Patent number: 10031131
    Abstract: The present invention provides for novel methods for regulating and detecting the cytosine methylation status of DNA. The invention is based upon identification of a novel and surprising catalytic activity for the family of TET proteins, namely TET1, TET2, TET3, and CXXC4. The novel activity is related to the enzymes being capable of converting the cytosine nucleotide 5-methylcytosine into 5-hydroxymethylcytosine by hydroxylation.
    Type: Grant
    Filed: February 23, 2017
    Date of Patent: July 24, 2018
    Assignees: THE CHILDREN'S MEDICAL CENTER CORPORATION, THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES
    Inventors: Anjana Rao, Mamta Tahiliani, Kian Peng Koh, Suneet Agarwal, Aravind Iyer
  • Patent number: 10017764
    Abstract: The present invention provides oligomeric compounds. Certain such oligomeric compounds are useful for hybridizing to a complementary nucleic acid, including but not limited, to nucleic acids in a cell. In certain embodiments, hybridization results in modulation of the amount activity or expression of the target nucleic acid in a cell.
    Type: Grant
    Filed: February 8, 2012
    Date of Patent: July 10, 2018
    Assignee: Ionis Pharmaceuticals, Inc.
    Inventors: Susan M. Freier, Eric E. Swayze
  • Patent number: 10000768
    Abstract: The invention relates to methods and compositions for increasing resistance or tolerance to a nematode plant pest in a plant or part thereof. Nucleotide sequences that confer resistance or tolerance to nematode plant pests when expressed in a plant are provided as well as compositions comprising the polypeptides encoded by the nucleotide sequences, and transgenic plants and parts thereof comprising the nucleotide sequences.
    Type: Grant
    Filed: November 20, 2012
    Date of Patent: June 19, 2018
    Assignees: Syngenta Participations AG, Evogene Ltd.
    Inventors: Dror Shalitin, Hagai Karchi, Xiang Huang
  • Patent number: 10000772
    Abstract: The present disclosure provides a DNA-targeting RNA that comprises a targeting sequence and, together with a modifying polypeptide, provides for site-specific modification of a target DNA and/or a polypeptide associated with the target DNA. The present disclosure further provides site-specific modifying polypeptides. The present disclosure further provides methods of site-specific modification of a target DNA and/or a polypeptide associated with the target DNA The present disclosure provides methods of modulating transcription of a target nucleic acid in a target cell, generally involving contacting the target nucleic acid with an enzymatically inactive Cas9 polypeptide and a DNA-targeting RNA. Kits and compositions for carrying out the methods are also provided. The present disclosure provides genetically modified cells that produce Cas9; and Cas9 transgenic non-human multicellular organisms.
    Type: Grant
    Filed: April 13, 2015
    Date of Patent: June 19, 2018
    Assignees: The Regents of the University of California, University of Vienna
    Inventors: Jennifer A. Doudna, Martin Jinek, Emmanuelle Charpentier, Krzysztof Chylinski
  • Patent number: 9995741
    Abstract: The present disclosure relates to a complex for detecting a target material comprising upconverting nanoparticles; and at least one target material specific aptamer-quencher, connected through a linker with the upconverting nanoparticles, a method of preparing the same, a kit for detecting a target material comprising the same, and a method of detecting a target material using the same. According to the present disclosure, different target materials in samples can be quantified or detected accurately based on luminescence resonance energy transfer (LRET) of the upconverting nanoparticles (UCNPs) excited by a near infrared (NIR) light source.
    Type: Grant
    Filed: August 5, 2016
    Date of Patent: June 12, 2018
    Assignee: GWANGJU INSTITUTE OF SCIENCE AND TECHNOLOGY
    Inventors: Min-Gon Kim, Eun-Jung Jo, Hyo-Young Mun
  • Patent number: 9994857
    Abstract: Aptamers having improved stability against nucleases that bind PDGF and aptamers that bind VEGF are provided. In addition, aptamer constructs comprising a PDGF aptamer and a VEGF aptamer are provided. Pharmaceutical compositions comprising the aptamers and aptamer constructs are provided, as well as methods of treating conditions using the aptamers and aptamer constructs.
    Type: Grant
    Filed: May 15, 2017
    Date of Patent: June 12, 2018
    Assignee: SOMALOGIC, INC.
    Inventors: Nebojsa Janjic, Daniel W. Drolet, Amy D. Gelinas, Chi Zhang, Michael Vrkljan
  • Patent number: 9970926
    Abstract: The invention relates to identification and characterization of recombinant DNA and polypeptides for specific Bt toxin receptors. In particular, the Bt toxin receptors of the invention include those derived from the Lepidopteran super family including the species Trichoplusiani ni, Pseudoplusia includens, Helicoverpa zea, and Spodoptera frugiperda. The receptors of the invention further include those derived from the Coleopteran super family and particularly from the species Diabrotica virgifera virgifera. The recombinant DNA and polypeptides so provided are useful in the identification and design of novel Bt toxin receptor ligands including novel or improved insecticidal toxins for use in a variety of agricultural applications. Materials and methods for identifying novel toxins are also disclosed herein. The invention also provides methods for selecting toxins to combine to control insect populations by manipulating Bt toxin receptor.
    Type: Grant
    Filed: November 20, 2014
    Date of Patent: May 15, 2018
    Assignee: Monsanto Technology LLC
    Inventors: Edward Kraft, Renata Bolognesi, Artem Evdokimov, Farhad Moshiri, Meiying Zheng, Victor M Guzov
  • Patent number: 9957556
    Abstract: The present invention is directed to methods, compositions and software for enriching low abundance alleles in a sample. It is directed in particular to the use of an excess amount of reference blocking sequence in an amplification reaction mixture in order to improve the enrichment efficiency, and reduce cycle time, of full COLD-PCR.
    Type: Grant
    Filed: December 16, 2013
    Date of Patent: May 1, 2018
    Assignee: Dana-Farber Cancer Institute, Inc.
    Inventor: Gerassimos Makrigiorgos
  • Patent number: 9951092
    Abstract: Methods, kits and devices for separating phospholipids and proteins from small molecules in biochemical samples can feature an apparatus having a wetting barrier, at least one fit and a separation media. For example, an apparatus can include at least one wall defining a chamber having an exit and an entrance; a wetting barrier disposed between the exit and entrance, so as to define a separation media space located between the wetting barrier and the exit and a sample receiving area located between the wetting barrier and the entrance; and a separation media disposed adjacent to the wetting barrier and having a specific affinity for phospholipids.
    Type: Grant
    Filed: May 20, 2011
    Date of Patent: April 24, 2018
    Assignee: Waters Technologies Corporation
    Inventors: Pamela C. Iraneta, Thomas H. Walter, Xin Zhang, Daniel P. Walsh, Kevin D. Wyndham, Raymond P. Fisk
  • Patent number: 9950068
    Abstract: Provided are formulations, compositions and methods for delivering biological moieties such as modified nucleic acids into cells to modulate protein expression. Such compositions and methods include the delivery of biological moieties, and are useful for production of proteins.
    Type: Grant
    Filed: December 14, 2016
    Date of Patent: April 24, 2018
    Assignee: ModernaTX, Inc.
    Inventors: Antonin De Fougerolles, Sayda M. Elbashir
  • Patent number: 9944996
    Abstract: The current invention relates to a diagnostic kit for a yeast or fungal species comprising at least one oligonucleotide probe capable of binding to at least a portion of the eIF2y gene or its corresponding mRNA.
    Type: Grant
    Filed: June 15, 2009
    Date of Patent: April 17, 2018
    Assignee: National University of Ireland, Galway
    Inventors: Thomas Gerard Barry, Majella Maher, Terry James Smith, Marcin Jankiewicz, Louise O'Connor, Nina Tuite, Sinead Lahiff
  • Patent number: 9903002
    Abstract: The present invention provides Salmonella non-coding RNA and the identification and application thereof. In particular, the present invention proves through experiments that a Salmonella bacterium delivers non-coding RNAs (ncRNAs) encoded by the bacterium itself into a host cell, generates milRNAs similar to microRNAs by means of a microRNA splicing system in the cell, regulates the immune system with the milRNAs, and further protects the Salmonella bacterium from being cleared by the host. Adsorbing milRNAs using milRNA inhibitors can effectively inhibit the survival ability of the bacterium in the cell, leading to a reduced vitality of the bacterium. The present invention further provides relevant reagents and methods for effective detection of, treatment to and study on Salmonella bacteria or Salmonella infectious diseases.
    Type: Grant
    Filed: December 9, 2014
    Date of Patent: February 27, 2018
    Assignee: JIANGSU MICROMEDMARK BIOTECH CO., LTD.
    Inventors: Ke Zeng, Hongwei Gu, Chenyu Zhang, Tianfu Zhang
  • Patent number: 9896473
    Abstract: The present invention relates to a thiol compound suitable for forming a chain of oligomers that can be grafted to an oligonucleotide. The invention also relates to an oligonucleotide grafted by such a compound, thus having one or more thiol functions, suitable for being immobilized on a gold surface or on a grafted surface.
    Type: Grant
    Filed: April 4, 2013
    Date of Patent: February 20, 2018
    Assignees: Etablissement Francais du Sang, Centre National de la Recherche Scientifique (CNRS)
    Inventors: François Morvan, Albert Meyer, Jean-Jacques Vasseur, Julie Mayen, Carole Chaix, Carole Farre, Chantal Fournier-Wirth, Jean-François Cantaloube, Myriam Lereau
  • Patent number: 9895312
    Abstract: The present invention discloses c-MYC-siRNA formulation as a potential therapeutic target for cisplatin-resistant ovarian cancer. It is disclosed targeting c-MYC with small interfering RNA (siRNA) in the cisplatin-resistant ovarian cancer cell line inducing a significant cell growth arrest and inhibition of cell proliferation. Apoptosis and arrest of cell cycle progression were also observed after c-MYC-siRNA-based silencing of c-MYC. Furthermore, delivering nanoliposomal c-MYC-siRNA, decreased tumor weight and number of tumor nodules compared with a liposomal-negative control siRNA.
    Type: Grant
    Filed: April 8, 2015
    Date of Patent: February 20, 2018
    Inventors: Pablo E. Vivas-Mejia, Jeyshka M. Reyes Gonzalez, Anil K. Sood
  • Patent number: 9889197
    Abstract: Diabody molecules and uses thereof in the treatment of a variety of diseases and disorders, including immunological disorders, infectious disease, intoxication and cancers are disclosed. The diabody molecules comprise two polypeptide chains that associate to form at least two epitope binding sites, which may recognize the same or different epitopes on the same or differing antigens. Additionally, the antigens may be from the same or different molecules. The individual polypeptide chains of the diabody molecule may be covalently bound through non-peptide bond covalent bonds, such as disulfide bonding of cysteine residues located within each polypeptide chain. The diabody molecules may further comprise an Fc region, which allows antibody-like functionality to be engineered into the molecule.
    Type: Grant
    Filed: July 29, 2011
    Date of Patent: February 13, 2018
    Assignee: MacroGenics, Inc.
    Inventors: Leslie S. Johnson, Ling Huang, Godfrey Jonah Anderson Rainey
  • Patent number: 9885082
    Abstract: Disclosed embodiments concern a probe comprising one or more pairs of monomers capable of targeting a nucleic acid target. The pair of monomers may be arranged in a manner that promotes thermoinstability of the probe complex, thus producing a probe capable of locating and/or detecting a target. The probe also may comprise one or more natural or non-natural nucleotides capable of Watson-Crick base pairing with an isosequential nucleic acid target. Particular disclosed embodiments concern a method of using the disclosed probe to target nucleic acids. In particular disclosed embodiments, the probe may be incubated with a target nucleic acid and then be detected.
    Type: Grant
    Filed: July 19, 2012
    Date of Patent: February 6, 2018
    Assignee: University of Idaho
    Inventor: Patrick Jerzy Hrdlicka
  • Patent number: 9879261
    Abstract: The technology described herein relates to double-stranded ribonucleic acid (dsRNA) compositions targeting the Serpina1 gene, and methods of using such dsRNA compositions to inhibit expression of Serpina1.
    Type: Grant
    Filed: December 18, 2015
    Date of Patent: January 30, 2018
    Assignee: ALNYLAM PHARMACEUTICALS, INC.
    Inventors: Alfica Sehgal, David Bumcrot, Brian Bettencourt
  • Patent number: 9879255
    Abstract: The present invention provides oligonucleotides that inhibit the binding of miR-27a to VE-cadherin mRNA, particularly in the form of blockmirs. The invention also provides compositions comprising such oligonucleotides and methods of use of such oligonucleotides to modulate the activity of VE-cadherin, inhibit or reduce vascular permeability, treat or prevent a vascular permeability-associated disease or condition, inhibit tumor growth, treat ischaemic injury, enhance recovery from ischaemic injury, treat surgical wounds and/or promotes post-operative recovery, and promote or induce angiogenesis.
    Type: Grant
    Filed: October 2, 2013
    Date of Patent: January 30, 2018
    Assignee: University of Newcastle Upon Tyne
    Inventors: Jennifer Gamble, Mathew Vadas, Thorleif Moller
  • Patent number: 9873916
    Abstract: This invention relates to a composition and a method for prediction of a response to Trastuzumab therapy in a breast cancer patient, and more specifically, a composition, a kit, a DNA chip, and a method for predicting a response to Trastuzumab therapy by using polynucleotides each comprising a nucleotide sequence represented by any of SEQ ID NOs: 1 to 9, 11 to 19, and 21 to 23 in the Sequence Listing or a nucleotide sequence derived therefrom by substitution of u with t, mutants thereof, derivatives thereof, or fragments thereof comprising at least 16 continuous nucleotides, or a polynucleotide comprising a complementary sequence thereof, and using an increase or decrease in Her2 protein expression level as an indicator.
    Type: Grant
    Filed: April 25, 2012
    Date of Patent: January 23, 2018
    Assignees: TORAY INDUSTRIES, INC., KYOTO UNIVERSITY
    Inventors: Akira Myomoto, Satoko Kozono, Fumiaki Sato, Masakazu Toi, Takayuki Ueno, Zhipeng Wang, Gozoh Tsujimoto, Kazuharu Shimizu
  • Patent number: 9868955
    Abstract: Provided herein are human Toll-like receptor (TLR)-inhibitors and methods for use in individuals having an autoimmune disease or an inflammatory disorder. The TLR inhibitors of the present disclosure are polynucleotides comprising an inhibitory motif for one or more of TLR7, TLR8 and TLR9.
    Type: Grant
    Filed: September 27, 2013
    Date of Patent: January 16, 2018
    Assignee: Dynavax Technologies Corporation
    Inventors: Cristiana Guiducci, Karen L. Fearon, Franck Barrat
  • Patent number: 9868958
    Abstract: Described are compositions and methods relating to variant filamentous fungi having altered growth characteristics. Such variants are well-suited for growth in submerged cultures, e.g., for the large-scale production of enzymes and other proteins for commercial applications.
    Type: Grant
    Filed: April 20, 2012
    Date of Patent: January 16, 2018
    Assignee: DANISCO US INC.
    Inventors: Elizabeth A. Bodie, Robert James Pratt, II
  • Patent number: 9850540
    Abstract: The present invention relates to a method for detecting lung cancer using a lung cancer-specific biomarker, and more particularly to a biomarker for lung cancer diagnosis, which can detect methylation of PCDHGA12 gene whose 5?UTR or exon 1 region is specifically methylated in lung cancer cells, and to a method of detecting lung cancer and the stage of its progression using the biomarker. The diagnostic kit according to the present invention makes it possible to diagnose lung cancer at an early stage in an accurate and rapid manner compared to conventional methods and can be used for prognosis and monitoring of lung cancer and the stage of its progression.
    Type: Grant
    Filed: February 18, 2009
    Date of Patent: December 26, 2017
    Assignee: GENOMICTREE, INC.
    Inventors: Sung Whan An, Young Ho Moon, Tae Jeong Oh